Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 29.7% in January

Atossa Genetics Inc. (NASDAQ:ATOS) saw a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 4,696,759 shares, a growth of 29.7% from the January 15th total of 3,621,023 shares. Approximately 60.2% of the shares of the stock are sold short. Based on an average daily volume of 2,992,317 shares, the short-interest ratio is presently 1.6 days. Based on an average daily volume of 2,992,317 shares, the short-interest ratio is presently 1.6 days. Approximately 60.2% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Atossa Genetics by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock worth $5,270,000 after acquiring an additional 245,717 shares in the last quarter. Ameriprise Financial Inc. acquired a new position in shares of Atossa Genetics in the 2nd quarter valued at about $2,468,000. Renaissance Technologies LLC lifted its position in shares of Atossa Genetics by 33.2% in the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after purchasing an additional 514,175 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Atossa Genetics by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock worth $810,000 after purchasing an additional 9,627 shares during the period. Finally, State Street Corp grew its position in Atossa Genetics by 31.2% during the fourth quarter. State Street Corp now owns 596,485 shares of the company’s stock valued at $352,000 after purchasing an additional 141,990 shares in the last quarter. 12.74% of the stock is owned by institutional investors and hedge funds.

Atossa Genetics Price Performance

ATOS stock opened at $4.20 on Monday. The firm has a market capitalization of $36.20 million, a P/E ratio of -1.17 and a beta of 1.36. Atossa Genetics has a 52-week low of $3.76 and a 52-week high of $19.35. The company’s 50 day simple moving average is $9.04 and its 200-day simple moving average is $11.37.

Analyst Upgrades and Downgrades

ATOS has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Atossa Genetics in a research note on Wednesday, January 21st. Ascendiant Capital Markets increased their price objective on Atossa Genetics from $116.25 to $120.00 and gave the company a “buy” rating in a research report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, Atossa Genetics has a consensus rating of “Hold” and a consensus price target of $95.00.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.